Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 274

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 274
---
, which supported moving forward with the transaction. The due diligence included: •meetings and calls with the management team, board members, shareholders and advisors of the Company regarding, among other things, the Company’s technology, commercialization plans (including through potential retail partners in Latin America and market opportunity (including potential expansion into Latin American jurisdictions outside of Argentina and Paraguay); •review of the Company’s material contracts and other agreements, including its governing documents and instruments and agreements related to key intellectual property, clients, vendors, suppliers, advisors, joint ventures, partnerships, consultants, employees, contractors, indemnities and any prior acquisitions, mergers and/or dispositions; •financial, tax, legal, insurance, accounting, operational, business and other due diligence, including reviews of board meeting minutes and resolutions, labor and employment matters, the Company’s corporate and management structure (including that of affiliates and subsidiaries), intellectual property, investor agreements and capitalization tables, prior communications made with shareholders or other holders of company securities, prior insider transactions, prior restructuring and recapitalizations, legal proceedings, legal compliance with applicable laws and regulations, privacy/data security, regulatory licenses, permits, approvals and authorizations, tax matters and critical third -partyvendor arrangements; •analysis of revenue and EBITDA of comparable companies in the genomics, artificial intelligence, healthcare data, diagnostics and digital healthcare sectors from various stages in development, including early stage, growth and mature companies, that were listed on either NYSE or Nasdaq with market capitalizations ranging from approximately $20 million to over $10 billion; •the comparable companies and the relevant financial information considered is set forth below:

| Company Name                            |     | Symbol        |     |      Equity 
 Value(1)(2) |   |     |       2023 
 Revenue(1) |     | 2023      
 EBITDA(1) |   |
| Genomics Companies                      |     |               |     |             |   |     |            |     |           |   |
| Intellia Therapeutics, Inc.             |     | NASDAQ:NTLA   |     |       1,859 |   |     |         36 |     | (506      | ) |
| 10x Genomics, Inc.                      |     | NASDAQ:TXG    |     |       4,297 |   |     |        619 |     | (159      | ) |
| uniQure N.V.                            |     | NASDAQ:Q